New Trends in Target Validation: Decoding Competitive ABPP
- Samples are divided into a drug-treated group and a control group.
- ABP probes are added to each group for standard active-site labeling.
- Proteins are enriched and digested, while retaining probe-labeled active enzymes for analysis.
- Mass spectrometry is used to compare the extent of probe labeling for individual enzymes between the two groups.
- Changes in probe signal are used to determine whether the drug directly competes for binding to the enzyme active site.
- Support for multiple classes of enzyme-directed probes, including probes targeting serine enzymes, cysteine-dependent enzymes, and metalloproteinases.
- Broad sample compatibility, including cell lines, animal tissues, and human biospecimens.
- Reliable quantitative performance based on a high-resolution mass spectrometry platform for peptide identification and quantification.
- Comprehensive binding inhibition analysis reports, including competition-rate calculation, target prioritization, GO/KEGG annotation, and graphical data output.
- Support for iterative validation study design, including structure optimization, dose-gradient evaluation, and time-course analysis.
In drug discovery and development, target screening does not equate to target confirmation. Even if a candidate protein is repeatedly identified through differential expression analysis or pathway enrichment analysis, this does not necessarily mean that it is a direct drug target. The key questions are:
Is this protein a direct target of the drug? Does covalent binding occur? Is the inhibition selective? Are there potential off-target effects?
These questions are difficult to address directly using conventional proteomic and molecular biological approaches. As an extended and enhanced form of activity-based protein profiling, competitive ABPP (Competitive Activity-Based Protein Profiling) is emerging as a new trend and a new standard in target validation. Building on its ABPP platform, MtoZ Biolabs has established a competitive ABPP workflow that has been widely applied in the evaluation of novel covalent inhibitors, activity validation of natural products, and off-target risk assessment of lead compounds.
What Is Competitive ABPP?
Conventional ABPP (Activity-Based Protein Profiling) uses covalent activity-based probes (ABPs) to label active proteins and, in combination with mass spectrometry, enables the identification and quantification of these functionally active enzymes. It is commonly used for functional protein profiling and drug target discovery.
Competitive ABPP is a functional proteomics strategy designed to strengthen target validation by introducing a competition-based drug-binding mechanism. The core principle is that a small-molecule drug and an active-site-directed probe compete for access to the same enzymatic active site, thereby allowing investigators to infer whether the drug directly engages the target enzyme. Although competitive ABPP is built upon classical ABPP, it incorporates a critical competitive design step in which the sample is first treated with the drug and then labeled with the probe. The basic workflow is as follows:
If the signal intensity of a given enzyme is markedly reduced in the drug-treated group, this indicates that the drug has strong affinity for the active site of that enzyme, suggesting that it is a candidate direct target. Conversely, if the signal remains unchanged, the enzyme is unlikely to be directly engaged by the drug, or the observed binding is unlikely to reflect target-specific interaction.
Unique Advantages of Competitive ABPP
Compared with conventional proteomics and chemical proteomics approaches, competitive ABPP offers multidimensional advantages:
1. Function-Centered Readout
Competitive ABPP focuses on protein activity rather than total abundance or expression level, enabling the identification of functional targets that genuinely participate in physiological processes under disease conditions or drug stimulation.
2. Direct Readout of Binding Events
By comparing differences in probe labeling before and after drug treatment, researchers can directly assess whether a drug acts on the catalytic center of a specific enzyme, thereby avoiding the complicated indirect interpretation often required in traditional validation workflows.
3. Simultaneous Assessment of Selectivity and Off-Target Effects
Competitive ABPP can not only confirm whether a drug acts on the intended target enzyme, but also evaluate its effects on non-target enzymes within the same experimental system. This provides important guidance for structure optimization and reduction of toxicity-related risks.
4. Broad Technical Compatibility
This strategy is compatible with cell lysates, tissue homogenates, and even in vivo labeling systems. It is therefore well suited for validation studies across multiple model systems and offers strong translational potential.
Why Is Competitive ABPP Becoming a New Standard for Target Validation?
1. Direct Identification of Target Engagement
Compared with differential protein screening approaches, competitive ABPP can directly determine whether a drug physically engages a specific enzyme, making it one of the most reliable strategies currently available for confirming covalent targets.
2. Evaluation of Drug Selectivity
By measuring the extent of competition, competitive ABPP can assess the affinity and selectivity of a drug across different enzymes, thereby supporting structure optimization and side-effect control.
3. Detection of Off-Target Activity
Competitive ABPP can reveal unintended interactions with non-target enzymes, thereby providing early warning of potential toxicity or mechanistic interference.
4. Compatibility With Covalent Drug Development Pipelines
In the development of multiple covalent drugs, including Ibrutinib, Neratinib, and Afatinib, competitive ABPP has been widely used for target-validation studies conducted prior to regulatory submission.
Professional Support From The MtoZ Biolabs Competitive ABPP Platform
As a core platform in functional proteomics, MtoZ Biolabs has established a standardized end-to-end service system for competitive ABPP, covering probe screening, sample preparation, mass spectrometric analysis, and target data interpretation:
Traditional target studies often rely on repeated rounds of expression validation and functional inference, making it difficult to rapidly define the direct relationship between a drug and its enzymatic target. Competitive ABPP provides a clearer and more logically rigorous validation strategy: it uses competitive blockade to demonstrate binding and differential signal change to confirm direct target engagement. Within the research logic chain of expression, function, and mechanism of action, competitive ABPP is increasingly becoming a pivotal technical bridge.
MtoZ Biolabs, an integrated chromatography and mass spectrometry (MS) services provider.
Related Services
How to order?
